Clinical Trials Browser

Phase 2/3 × Interventional × Brentuximab Vedotin × Clear all

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Phase 2/3 Recruiting

Hodgkin Disease, Recurrence